Search research articles
Contact Us
Filters
Showing results (231-240 of 425) with videos related to
Page
of 43
Sort By:
Current Atherosclerosis Reports
|
August 4, 2021
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
Arrigo F G Cicero, Federica Fogacci, Anca Pantea Stoian, et al.
Nutrients
|
March 6, 2021
Efficacy and Safety of Armolipid Plus<sup>®</sup>: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Arrigo F G Cicero, Cormac Kennedy, Tamara Knežević, et al.
American Journal of Preventive Cardiology
|
August 11, 2025
High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels
Beata Franczyk, Ewelina Młynarska, Magdalena Rysz-Górzyńska, et al.
Journal of the American Heart Association
|
July 8, 2016
Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
Anthony Wang, Akshara Richhariya, Shravanthi R Gandra, et al.
Atherosclerosis
|
March 14, 2012
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials
Doralisa Morrone, William S Weintraub, Peter P Toth, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 12, 2016
Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study
Jacquelaine Bartlett, Irene M Predazzi, Scott M Williams, et al.
American Journal of Preventive Cardiology
|
March 28, 2022
Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
Nathan D Wong, Matthew J Budoff, Keith Ferdinand, et al.
Expert Opinion on Investigational Drugs
|
August 3, 2024
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations
Ruben Casado-Arroyo, Marco Bernardi, Pierre Sabouret, et al.
The American Journal of Cardiology
|
August 29, 2017
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus
Naveed Sattar, Peter P Toth, Dirk J Blom, et al.
American Journal of Preventive Cardiology
|
September 2, 2025
High-density lipoproteins. Part 2. Impact of disease states on functionality
Anna Gluba-Sagr, Robert Olszewski, Beata Franczyk, et al.
Page
of 43
Search research articles
Search
Showing results (231-240 of 425) with videos related to
Sort By:
Page
of 43
Current Atherosclerosis Reports
|
August 4, 2021
Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels?
Arrigo F G Cicero, Federica Fogacci, Anca Pantea Stoian, et al.
Nutrients
|
March 6, 2021
Efficacy and Safety of Armolipid Plus<sup>®</sup>: An Updated PRISMA Compliant Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Arrigo F G Cicero, Cormac Kennedy, Tamara Knežević, et al.
American Journal of Preventive Cardiology
|
August 11, 2025
High-density lipoproteins, Part 1. Epidemiology, antiatherogenic effects, and therapies designed to increase their serum levels
Beata Franczyk, Ewelina Młynarska, Magdalena Rysz-Górzyńska, et al.
Journal of the American Heart Association
|
July 8, 2016
Systematic Review of Low-Density Lipoprotein Cholesterol Apheresis for the Treatment of Familial Hypercholesterolemia
Anthony Wang, Akshara Richhariya, Shravanthi R Gandra, et al.
Atherosclerosis
|
March 14, 2012
Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials
Doralisa Morrone, William S Weintraub, Peter P Toth, et al.
Circulation. Cardiovascular Quality and Outcomes
|
May 12, 2016
Is Isolated Low High-Density Lipoprotein Cholesterol a Cardiovascular Disease Risk Factor? New Insights From the Framingham Offspring Study
Jacquelaine Bartlett, Irene M Predazzi, Scott M Williams, et al.
American Journal of Preventive Cardiology
|
March 28, 2022
Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
Nathan D Wong, Matthew J Budoff, Keith Ferdinand, et al.
Expert Opinion on Investigational Drugs
|
August 3, 2024
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations
Ruben Casado-Arroyo, Marco Bernardi, Pierre Sabouret, et al.
The American Journal of Cardiology
|
August 29, 2017
Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus
Naveed Sattar, Peter P Toth, Dirk J Blom, et al.
American Journal of Preventive Cardiology
|
September 2, 2025
High-density lipoproteins. Part 2. Impact of disease states on functionality
Anna Gluba-Sagr, Robert Olszewski, Beata Franczyk, et al.
Page
of 43